Last updated 2 days ago
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
3500 patients around the world
Available in Argentina, United States
Metsera, a wholly owned subsidiary of Pfizer
11Research sites
3500Patients around the world
This study is for people with
Obesity
Requirements for the patient
To 99 Years
All Gender
Medical requirements
- BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to <30.0 kg/m2 and presence of at least 1 of the following weight-related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
- Have any form of diabetes.Have a self-reported body weight change > 5 kg (11 pounds) within 3 months prior to Screening.Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease.
Sites
Instituto de Investigaciones Clínicas Córdoba
Instituto de Investigaciones Clínicas Mar del Plata
Centro Médico Viamonte SRL - CABA, Buenos Aires
Centro Médico Privado de Reumatología - San Miguel de Tucumán
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Consultorio Integral de Atención al Diabético CIAD Morón
Instituto Medico Catamarca "IMEC"
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
Clínica Privada Vélez Sarsfield - Córdoba
CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegiani
StudyVESPER-4
SponsorMetsera, a wholly owned subsidiary of Pfizer
Study typeInterventional
Conditions
Obesity
Requirements
To 99 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07311850
